Table 4.
Testosterone, sex hormone-binding globulin, free androgen index and hair testosterone at baseline and during treatment with a combined oral contraceptive or placebo.
| Baseline | P | Treatment | Pa | |||
|---|---|---|---|---|---|---|
| COC (n = 97) | Placebo (n = 99) | COC (n = 76) | Placebo (n = 89) | |||
| Testosterone (nmol/L) | 1.54 (1.22–2.10) | 1.53 (1.25–2.00) | NS | 1.37 (1.04–1.77) | 1.67 (1.27–2.15) | 0.002 |
| SHBG | 72 (47–104) | 75 (54–99) | NS | 103 (74–129) | 62 (44–81) | 0.000 |
| Free androgen index | 2.40 (1.39–4.04) | 2.11 (1.39– 3.28) | NS | 1.44 (0.95–2.08) | 2.87 (1.80–4.57) | 0.000 |
| (n = 90) | (n = 87) | (n = 75) | (n = 78) | |||
| Hair testosterone (pg/mg) | 1.33 (1.02–1.92) | 1.28 (0.95–1.69) | NS | 1.26 (1.02–1.74) | 1.41 (1.00–1.81) | NS |
Data displayed as median (IQR).
aSignificant P values have been calculated on delta values treatment – baseline, Mann–Whitney U test.
COC, combined oral contraceptive; NS, not significant; SHBG, sex hormone-binding globulin.
This work is licensed under a